TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›HSCS›Financials
Annual statements · SEC XBRL · FY2022 – FY2025

HeartSciences Inc. (HSCS) financials

Income statement

HeartSciences Inc. (HSCS) income statement, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Revenue$14.4K$5.15K$18.6K$4.35K
Revenue growth—-64.2%261.2%-76.6%
Gross profit$6.48K$2.35K$12.5K$2.47K
Gross margin45.1%45.7%67.3%56.8%
Operating income-$4.71M-$6.11M-$6.31M-$8.35M
Operating margin-32765.6%-118698.3%-33902.0%-192013.1%
Net income-$4.83M-$6.35M-$6.61M-$8.77M
Net margin-33592.6%-123384.3%-35511.9%-201499.5%
EPS (diluted)-$1.45-$80.00-$18.74-$9.34

Cash flow

HeartSciences Inc. (HSCS) cash flow, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Operating cash flow-$3.64M-$5.77M-$6.07M-$7.41M
Capital expenditures$1.93K$18.3K$64.5K$3.16K
Free cash flow-$3.65M-$5.79M-$6.13M-$7.42M

Balance sheet

HeartSciences Inc. (HSCS) balance sheet, annual, from SEC filings
Fiscal yearFY2022FY2023FY2024FY2025
Cash & equivalents$918K$1.66M$5.81M$1.10M
Total assets$2.09M$3.29M$9.50M$4.22M
Total liabilities$8.15M$3.06M$2.19M$4.02M
Shareholders' equity-$6.06M$231K$7.32M$205K
Retained earnings-$54.4M-$60.8M-$67.4M-$76.1M
Shares (wtd avg diluted)3.32M79.5B353K938K

Every figure is extracted from HeartSciences Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is HeartSciences Inc.'s annual revenue?
HeartSciences Inc. (HSCS) reported $4.35K of revenue for fiscal year 2025 — down 76.6% from $18.6K in FY2024, per its annual report filed with the SEC.
Is HeartSciences Inc. profitable?
Not in FY2025 — HSCS reported a net loss of $8.77M, per SEC filings.
What is HeartSciences Inc.'s free cash flow?
-$7.42M in FY2025 (operating cash flow -$7.41M minus $3.16K of capital expenditures), from the SEC cash-flow statement.
Does HSCS pay a dividend?
HeartSciences Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full HSCS analysis — verdict, score & filings →Is HSCS a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.